Nigeria’s pharmaceutical companies relied heavily on short-term bank loans to fund operations, expansion, and working capital. That model is now under strain as rising interest rates and currency pressures make debt increasingly difficult to sustain. By the second quarter of 2026, a structural shift is taking hold, with firms beginning to restructure their balance sheets
Don't miss out on breaking stories and in-depth articles.
